Search clinical trials for: Atazanavir (Reyataz)

Total 198 results

Bristol-Myers Squibb

Completed

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

HIV

United States
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

HIV Infections

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Phoenix Children's Hospital
Bristol-Myers Squibb

Completed

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

HIV Infections | Pediatric HIV

United States
Bristol-Myers Squibb

Completed

Atazanavir Twice Daily

HIV Infections | Protease Inhibitor

United States
Northwestern University
Bristol-Myers Squibb

Completed

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study (SABAR)

HIV Infection | Hyperlipidemia

United States, Argentina, Italy
University of Roma La Sapienza

Unknown

ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir (ATAGLU)

HIV

Italy
Stanford University
Bristol-Myers Squibb

Completed

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

HIV Infections | Hyperlipidemia

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Genetics and HIV-1 Protease Inhibitors

HIV

United States
Brigham and Women's Hospital

Completed

Atazanavir and Endothelial Function in Older HIV Patients

HIV

United States
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

HIV-1 Infection | Immunosuppression-related Infectious Disease

France
Radboud University Medical Center

Completed

The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Sepsis | Inflammation | Endotoxemia | Multi Organ Dysfunction Syndrome

Netherlands
Bristol-Myers Squibb

Completed

Drug Interaction Study With Proton Pump Inhibitor

HIV Infections

United States
Bristol-Myers Squibb

Completed

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

HIV Infections

United States
Bristol-Myers Squibb

Completed

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) (INDUMA)

HIV Infections

Spain, Italy, United Kingdom, France, Russian Federation, Ireland, Germany, Latvia, Estonia, Portugal
Bristol-Myers Squibb

Completed

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (PRINCE1)

HIV Infections

Thailand, Chile, Peru, Brazil, Mexico, South Africa
Bristol-Myers Squibb

Completed

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

HIV Infections

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Completed

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Solid Tumor | Hematological Malignancies

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Healthy Volunteer

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Healthy Participants

United States
Yale University
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

HIV Infections | Human Immunodeficiency Virus | AIDS | Acquired Immune Deficiency Syndrome

United States
Kirby Institute

Completed

Raltegravir and Atazanavir Dosing Strategy Study (SPARTA)

HIV Infection

Australia
Catholic University of the Sacred Heart

Completed

Atazanavir and Lamivudine for Treatment Simplification (AtLaS)

HIV Infections

Italy
Bristol-Myers Squibb

Completed

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

HIV Infections | Protease Inhibitor

United States
Bristol-Myers Squibb

Completed

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

HIV

Argentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
Bristol-Myers Squibb

Completed

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (OREY)

Human Immunodeficiency Virus (HIV) Infections

Spain
Clinical Alliance for Research & Education - Infectious...
GlaxoSmithKline

Unknown

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

HIV Infections | Lipodystrophy

United States
Bristol-Myers Squibb

Completed

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (PRINCE2)

HIV

United States, Chile, Spain, South Africa, Mexico, Argentina, Poland, Brazil, Russian Federation, Romania, United Kingdom
Catholic University of the Sacred Heart

Completed

Atazanavir/r + Lamivudine Dual Therapy (ATLAS)

Human Immunodeficiency Virus

Italy
Ottawa Hospital Research Institute
Bristol-Myers Squibb

Completed

Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

HIV Infection

Canada
Radboud University Medical Center

Terminated

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (PRADAII)

HIV-1 Infection

Netherlands, Germany
Bristol-Myers Squibb

Completed

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

HIV, Pediatric

United States, Brazil, Chile, Mexico, Peru, South Africa, Argentina, Russian Federation
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland
ViiV Healthcare
GlaxoSmithKline

Completed

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) (ASSURE)

Infection, Human Immunodeficiency Virus

United States, Puerto Rico
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Bristol-Myers Squibb

Completed

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

HIV Infections

United States, United Kingdom
Bristol-Myers Squibb

Completed

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

HIV Infections

United States, Puerto Rico
Bristol-Myers Squibb

Completed

ATV/Ritonavir Nevirapine Interaction (USPAC)

HIV Infections

United Kingdom, United States
The University of Texas Health Science Center,...

Completed

"The Once A Day Protease Inhibitor Regimens"

HIV Infections

United States
Bristol-Myers Squibb

Completed

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

HIV Infections

United States, Canada
Bristol-Myers Squibb

Withdrawn

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (SUPPRESS)

HIV

United States
Hospitales Universitarios Virgen del Rocío
Bristol-Myers Squibb

Completed

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

HIV Infection | Hepatitis C, Chronic

Spain
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Metabolic Effects of Switching Kaletra to Boosted Reyataz

HIV Infections

United States
Radboud University Medical Center

Completed

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat (DATE-4)

Hepatitis C | HIV

Netherlands
Bristol-Myers Squibb

Completed

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

HIV Infections

Chile, Portugal, Spain, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Costa Rica, Dominican Republic, France, Germany, Guatemala, Hong Kong, Indonesia, Mexico, Netherlands, Panama, Peru, Puerto... and more
Bristol-Myers Squibb

Completed

Drug Interaction Study

Antivirals/HIV

United States
St Stephens Aids Trust

Completed

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

HIV Infections | HIV

United Kingdom
Bristol-Myers Squibb

Completed

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

HIV Infections

United States

Search clinical trials for: Atazanavir (Reyataz)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations